The Danish Pharmaceutical Novo Nordisk responds to political pressure and competition by reducing the price of his blockbuster medication in the USA.
• Novo Nordisk has reduced the US Prize for Ozempic for non-insured US patients
• Novo Nordisk share wins
• Step is considered a response to political pressure and competition
The Danish pharmaceutical company Novo Nordisk has massively reduced the US price of his blockbuster medication Ozempic for non-insured patients. The announcement, which fulfills the political demands of the Trump administration, led to a significant increase in the share.
Price for non-insured patients massively reduced
As the Financial Times reports, Novo Nordisk has halved the monthly price for Ozempic in the USA for patients without health insurance. The drug that is primarily used to treat diabetes, but also serves to reduce weight, now costs $ 499 per month. Previously, the price for this patient group was around $ 1,000. However, the reduction only affects a small part of the users, since the company states that 98 percent of the patients receive the drug through their health insurance and only pay $ 25 or less. In addition, Ozempic should also be available for the first time by delivery via the pharmacy own divocare divocare divocare divocare divocare divocare and in cooperation with the telemedicine provider Goodrx. This announcement in Monday trading at NASDAQ, especially the Goodrx share, helped the legs: the papers ultimately increased $ 37.27 percent to $ 5.12. On Tuesday, however, at times by 7.2 percent to $ 4.7513.
Novo Nordisk share course reaction surprises analysts
The Novo Nordisk share in Denmark ultimately rose by 6.63 percent to 347.50 Danish crowns after reporting in yesterday’s trade, which surprised analysts. On Tuesday, it will be 0.3 percent up to 348.55 DKK at times. Although a price reduction appears negative at first glance, investors rated it as a strategic step. The Danish group and its main competitor Eli Lilly from the United States have already lost $ 252 billion in market value this year due to concerns about political price controls, tariffs and competition. The price reduction for non-insured patients is considered a measure to counteract this concerns and to meet the political demands. Novo Nordisk had already reduced the price of his weight loss medication in Wegovy to $ 499 in March.
Background: political pressure and copies
The decision is related to the increasing pressure of the US government Pharmaceutical industryto lower the drug prices. President Trump sent letters to Novo Nordisk and 16 other pharmaceutical manufacturers in July, in which he asked them to lower prices and introduce direct sales models, reports CNBC. Another reason for the step is the competition through so -called “Compounded Drugs”, which are tailor -made copies of the original medication. These were widespread in the United States during an official scarcity of the active ingredient Semaglutid. Novo Nordisk estimates that about one million Americans use these copies. The company had previously ended a partnership with the US elementary provider HIMS & HERS because it had marketed the copies that were not approved. The FDA published a security warning on these unauthorized medication this month.
Editor finance.net
By the way: Eli Lilly and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And secure new customer bonus!
Selected leverage products on Eli Lilly
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Eli Lilly
The lever must be between 2 and 20
Advertising